Published in J Virol on August 01, 1993
The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature (2003) 10.76
A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J (2004) 5.67
Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J Virol (2004) 5.35
Species-specific, postentry barriers to primate immunodeficiency virus infection. J Virol (1999) 4.54
Functional surfaces of the human immunodeficiency virus type 1 capsid protein. J Virol (2003) 4.47
Proteolytic refolding of the HIV-1 capsid protein amino-terminus facilitates viral core assembly. EMBO J (1998) 4.46
Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J Virol (1995) 4.45
The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J Virol (2003) 4.23
A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc Natl Acad Sci U S A (2004) 3.73
HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology (2008) 3.72
The nuclear localization signal of the matrix protein of human immunodeficiency virus type 1 allows the establishment of infection in macrophages and quiescent T lymphocytes. Proc Natl Acad Sci U S A (1994) 3.65
Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J Virol (2006) 3.63
A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc Natl Acad Sci U S A (2004) 3.60
Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J Virol (2006) 3.27
The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes. J Virol (1996) 3.22
A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc Natl Acad Sci U S A (2004) 2.99
Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res (2010) 2.96
Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J Virol (2007) 2.95
Small-molecule inhibition of HIV-1 Vif. Nat Biotechnol (2008) 2.83
An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. J Virol (1998) 2.73
Role of the karyopherin pathway in human immunodeficiency virus type 1 nuclear import. J Virol (1996) 2.72
Highly purified human immunodeficiency virus type 1 reveals a virtual absence of Vif in virions. J Virol (1999) 2.66
Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J Virol (2007) 2.64
Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J Virol (2006) 2.63
Role of matrix in an early postentry step in the human immunodeficiency virus type 1 life cycle. J Virol (1998) 2.62
G-->A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol (2005) 2.61
APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog (2008) 2.60
Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect. J Virol (2006) 2.58
Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res (2007) 2.49
Human immunodeficiency virus type 1 Vif- mutant particles from restrictive cells: role of Vif in correct particle assembly and infectivity. J Virol (1995) 2.45
APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos Trans R Soc Lond B Biol Sci (2009) 2.40
The Vif and Gag proteins of human immunodeficiency virus type 1 colocalize in infected human T cells. J Virol (1997) 2.39
Subcellular localization of the Vif protein of human immunodeficiency virus type 1. J Virol (1994) 2.35
Complementation of vif-defective human immunodeficiency virus type 1 by primate, but not nonprimate, lentivirus vif genes. J Virol (1995) 2.35
Role of Vif in human immunodeficiency virus type 1 reverse transcription. J Virol (1996) 2.35
Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. J Virol (2004) 2.34
Inhibition of tRNA₃(Lys)-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication. J Virol (2006) 2.32
The role of Gag in human immunodeficiency virus type 1 virion morphogenesis and early steps of the viral life cycle. J Virol (1996) 2.31
Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 Vif protein. J Virol (1996) 2.30
Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. J Virol (2004) 2.27
The Vif protein of human and simian immunodeficiency viruses is packaged into virions and associates with viral core structures. J Virol (1995) 2.25
The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction. J Virol (2008) 2.21
Peripheral blood mononuclear cells produce normal amounts of defective Vif- human immunodeficiency virus type 1 particles which are restricted for the preretrotranscription steps. J Virol (1995) 2.19
Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA. J Virol (2001) 2.16
Human immunodeficiency virus type 1 integrase protein promotes reverse transcription through specific interactions with the nucleoprotein reverse transcription complex. J Virol (1999) 2.16
Human immunodeficiency virus type 1 Vif protein is an integral component of an mRNP complex of viral RNA and could be involved in the viral RNA folding and packaging process. J Virol (2000) 2.11
Association of human immunodeficiency virus type 1 Vif with RNA and its role in reverse transcription. J Virol (2000) 2.00
Aberrant Gag protein composition of a human immunodeficiency virus type 1 vif mutant produced in primary lymphocytes. J Virol (1995) 1.97
APOBEC3G genetic variants and their influence on the progression to AIDS. J Virol (2004) 1.97
Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J Virol (1998) 1.97
Early steps of retrovirus replicative cycle. Retrovirology (2004) 1.94
RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1. PLoS Pathog (2009) 1.84
Replication and pathogenicity of human immunodeficiency virus type 1 accessory gene mutants in SCID-hu mice. J Virol (1996) 1.80
Human immunodeficiency virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins. J Virol (1996) 1.76
Mice transgenic for human CD4 and CCR5 are susceptible to HIV infection. Proc Natl Acad Sci U S A (1997) 1.74
Human immunodeficiency virus type 1 replication is modulated by host cyclophilin A expression levels. J Virol (1998) 1.73
Characterization of human immunodeficiency virus type 1 Vif particle incorporation. J Virol (1996) 1.69
Partial rescue of the Vif-negative phenotype of mutant human immunodeficiency virus type 1 strains from nonpermissive cells by intravirion reverse transcription. J Virol (2000) 1.60
Regulation of human immunodeficiency virus type 1 infectivity by the ERK mitogen-activated protein kinase signaling pathway. J Virol (1999) 1.60
Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif. J Virol (2008) 1.59
Minimum requirements for efficient transduction of dividing and nondividing cells by feline immunodeficiency virus vectors. J Virol (1999) 1.58
Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells. Retrovirology (2004) 1.56
Human immunodeficiency virus type 1 Vif protein binds to the Pr55Gag precursor. J Virol (1997) 1.55
Human immunodeficiency virus type 1 vectors efficiently transduce human hematopoietic stem cells. J Virol (1998) 1.54
Mutational analysis of the human immunodeficiency virus type 1 Vif protein. J Virol (1999) 1.52
Defective accessory genes in a human immunodeficiency virus type 1-infected long-term survivor lacking recoverable virus. J Virol (1995) 1.50
Interactions of murine APOBEC3 and human APOBEC3G with murine leukemia viruses. J Virol (2008) 1.50
Human immunodeficiency virus type 1 Vif is efficiently packaged into virions during productive but not chronic infection. J Virol (2003) 1.49
Mutational analysis of the HIV-1 auxiliary protein Vif identifies independent domains important for the physical and functional interaction with HIV-1 reverse transcriptase. Nucleic Acids Res (2009) 1.48
The APOBEC3 family of retroelement restriction factors. Curr Top Microbiol Immunol (2013) 1.46
Further investigation of simian immunodeficiency virus Vif function in human cells. J Virol (2004) 1.46
Molecular biology of the human immunodeficiency virus accessory proteins. J Virol (1994) 1.44
Vif and the p55(Gag) polyprotein of human immunodeficiency virus type 1 are present in colocalizing membrane-free cytoplasmic complexes. J Virol (1999) 1.44
Cysteine residues in the Vif protein of human immunodeficiency virus type 1 are essential for viral infectivity. J Virol (1994) 1.42
Comprehensive investigation of the molecular defect in vif-deficient human immunodeficiency virus type 1 virions. J Virol (2003) 1.41
Phenotypically Vif- human immunodeficiency virus type 1 is produced by chronically infected restrictive cells. J Virol (1997) 1.38
Transduction of human progenitor hematopoietic stem cells by human immunodeficiency virus type 1-based vectors is cell cycle dependent. J Virol (1999) 1.37
Biological activity of human immunodeficiency virus type 1 Vif requires membrane targeting by C-terminal basic domains. J Virol (1995) 1.36
Conserved footprints of APOBEC3G on Hypermutated human immunodeficiency virus type 1 and human endogenous retrovirus HERV-K(HML2) sequences. J Virol (2008) 1.36
Role of Vif in stability of the human immunodeficiency virus type 1 core. J Virol (2000) 1.34
Restriction of retroviral replication by APOBEC3G/F and TRIM5alpha. Trends Microbiol (2008) 1.33
Susceptibility of rat-derived cells to replication by human immunodeficiency virus type 1. J Virol (2001) 1.33
Requirements for efficient production and transduction of human immunodeficiency virus type 1-based vectors. J Virol (1999) 1.32
The multimerization of human immunodeficiency virus type I Vif protein: a requirement for Vif function in the viral life cycle. J Biol Chem (2000) 1.32
Addition of deoxynucleosides enhances human immunodeficiency virus type 1 integration and 2LTR formation in resting CD4+ T cells. J Virol (2007) 1.31
Genetic dissociation of the encapsidation and reverse transcription functions in the 5' R region of human immunodeficiency virus type 1. J Virol (1999) 1.29
APOBECs and virus restriction. Virology (2015) 1.27
The various Sendai virus C proteins are not functionally equivalent and exert both positive and negative effects on viral RNA accumulation during the course of infection. J Virol (1998) 1.27
APOBEC3G induces a hypermutation gradient: purifying selection at multiple steps during HIV-1 replication results in levels of G-to-A mutations that are high in DNA, intermediate in cellular viral RNA, and low in virion RNA. Retrovirology (2009) 1.27
Molecular biology and pathogenesis of animal lentivirus infections. Clin Microbiol Rev (1996) 1.26
Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development. Trends Pharmacol Sci (2009) 1.24
vif-negative human immunodeficiency virus type 1 persistently replicates in primary macrophages, producing attenuated progeny virus. J Virol (1996) 1.22
A critical role for the TAR element in promoting efficient human immunodeficiency virus type 1 reverse transcription. J Virol (1996) 1.22
Zinc binding to the HCCH motif of HIV-1 virion infectivity factor induces a conformational change that mediates protein-protein interactions. Proc Natl Acad Sci U S A (2006) 1.20
Small molecular compounds inhibit HIV-1 replication through specifically stabilizing APOBEC3G. J Biol Chem (2010) 1.18
Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature (1985) 30.62
Nucleotide sequence of Moloney murine leukaemia virus. Nature (1981) 24.82
HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell (1990) 17.60
Purification of a RAS-responsive adenylyl cyclase complex from Saccharomyces cerevisiae by use of an epitope addition method. Mol Cell Biol (1988) 13.78
Genome organization and transactivation of the human immunodeficiency virus type 2. Nature (1987) 11.79
Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science (1990) 10.59
Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome. Science (1984) 10.40
HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. Nature (1990) 9.72
Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression. J Virol (1989) 9.37
Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci U S A (1988) 9.35
Sequence of simian immunodeficiency virus from macaque and its relationship to other human and simian retroviruses. Nature (1987) 7.96
The HIV 'A' (sor) gene product is essential for virus infectivity. Nature (1987) 7.51
Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. Nature (1991) 6.79
The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science (1987) 6.16
Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol (1992) 5.85
Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity. J Virol (1990) 5.01
Partial reverse transcripts in virions from human immunodeficiency and murine leukemia viruses. J Virol (1992) 4.72
Nucleotide sequence and genomic organization of feline immunodeficiency virus. Proc Natl Acad Sci U S A (1989) 4.57
HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus. Cell (1989) 4.40
Expanded HIV-1 cellular tropism by phenotypic mixing with murine endogenous retroviruses. Science (1990) 4.28
Replicative and cytopathic potential of HTLV-III/LAV with sor gene deletions. Science (1986) 4.04
Viral DNA carried by human immunodeficiency virus type 1 virions. J Virol (1992) 3.93
An RNA sequence of hundreds of nucleotides at the 5' end of poliovirus RNA is involved in allowing viral protein synthesis. J Virol (1988) 3.93
Interferons and bacterial lipopolysaccharide protect macrophages from productive infection by human immunodeficiency virus in vitro. J Exp Med (1989) 3.63
A new HTLV-III/LAV protein encoded by a gene found in cytopathic retroviruses. Science (1986) 3.20
Human immunodeficiency virus as a prototypic complex retrovirus. J Virol (1991) 3.19
Cell-dependent requirement of human immunodeficiency virus type 1 Vif protein for maturation of virus particles. J Virol (1993) 3.01
Human immunodeficiency virus pseudotypes with expanded cellular and species tropism. J Virol (1990) 2.66
Rev activates expression of the human immunodeficiency virus type 1 vif and vpr gene products. J Virol (1991) 2.62
Visna DNA synthesis and the tempo of infection in vitro. Virology (1982) 2.47
A human cell factor is essential for HIV-1 Rev action. EMBO J (1990) 2.43
Expression of human immunodeficiency virus type 1 vif and vpr mRNAs is Rev-dependent and regulated by splicing. Virology (1991) 2.43
Nucleotide sequence and genome organization of biologically active proviruses of the bovine immunodeficiency-like virus. Virology (1990) 2.36
Identification of HTLV-III/LAV sor gene product and detection of antibodies in human sera. Science (1986) 2.35
Nucleotide sequence and transcriptional analysis of molecular clones of CAEV which generate infectious virus. Virology (1990) 2.33
Transcription of novel open reading frames of AIDS retrovirus during infection of lymphocytes. Science (1985) 2.28
Cell-free transmission of Vif mutants of HIV-1. Virology (1992) 2.13
The pseudotypic paradox. J Gen Virol (1982) 1.83
Recombinational analysis of a natural noncytopathic human immunodeficiency virus type 1 (HIV-1) isolate: role of the vif gene in HIV-1 infection kinetics and cytopathicity. J Virol (1991) 1.73
A specific inhibitor of cysteine proteases impairs a Vif-dependent modification of human immunodeficiency virus type 1 Env protein. J Virol (1991) 1.72
Identification of a feline immunodeficiency virus gene which is essential for cell-free virus infectivity. J Virol (1992) 1.59
Visna virus DNA: discovery of a novel gapped structure. Virology (1981) 1.51
Interaction of a noncytopathic human immunodeficiency virus type 1 (HIV-1) with target cells: efficient virus entry followed by delayed expression of its RNA and protein. Virology (1990) 1.33
Minus-strand DNA is present within murine type C ecotropic retroviruses prior to infection. J Virol (1993) 1.14
In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science (1996) 28.95
A third-generation lentivirus vector with a conditional packaging system. J Virol (1998) 16.07
Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol (1997) 12.11
The genome of the social amoeba Dictyostelium discoideum. Nature (2005) 9.18
Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A (1996) 9.15
Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol (1998) 8.21
The role of knee alignment in disease progression and functional decline in knee osteoarthritis. JAMA (2001) 7.15
Guided medication dosing for inpatients with renal insufficiency. JAMA (2001) 6.25
Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell (1994) 5.92
Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol (1999) 5.35
Cells nonproductively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: a molecular model for latency. Cell (1990) 4.78
HIV-1 infection of nondividing cells through the recognition of integrase by the importin/karyopherin pathway. Proc Natl Acad Sci U S A (1997) 4.59
Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J Virol (1995) 4.45
HIV-1 infection of nondividing cells: C-terminal tyrosine phosphorylation of the viral matrix protein is a key regulator. Cell (1995) 4.41
Golgi dispersal during microtubule disruption: regeneration of Golgi stacks at peripheral endoplasmic reticulum exit sites. Mol Biol Cell (1996) 4.37
HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase. Cell (1995) 4.25
Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science (2000) 3.89
Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst (2001) 3.88
The nuclear localization signal of the matrix protein of human immunodeficiency virus type 1 allows the establishment of infection in macrophages and quiescent T lymphocytes. Proc Natl Acad Sci U S A (1994) 3.65
Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol (1997) 3.37
OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity (2001) 3.08
Cell-surface expression of CD4 reduces HIV-1 infectivity by blocking Env incorporation in a Nef- and Vpu-inhibitable manner. Curr Biol (1999) 2.97
HIV-1 Nef protein binds to the cellular protein PACS-1 to downregulate class I major histocompatibility complexes. Nat Cell Biol (2000) 2.95
Nef-induced CD4 degradation: a diacidic-based motif in Nef functions as a lysosomal targeting signal through the binding of beta-COP in endosomes. Cell (1999) 2.89
Localization of endoplasmic reticulum in living and glutaraldehyde-fixed cells with fluorescent dyes. Cell (1984) 2.73
Role of the karyopherin pathway in human immunodeficiency virus type 1 nuclear import. J Virol (1996) 2.72
Ultrasound assessment of inflammation and renal tissue injury with microbubbles targeted to P-selectin. Circulation (2001) 2.70
Association of Nef with the human immunodeficiency virus type 1 core. J Virol (1999) 2.62
Cytoplasmic recruitment of INI1 and PML on incoming HIV preintegration complexes: interference with early steps of viral replication. Mol Cell (2001) 2.53
The Nef protein of HIV-1 associates with rafts and primes T cells for activation. Proc Natl Acad Sci U S A (2000) 2.42
Local and nonlocal curvature elasticity in bilayer membranes by tether formation from lecithin vesicles. Biophys J (1992) 2.34
Lipopolysaccharide is a potent monocyte/macrophage-specific stimulator of human immunodeficiency virus type 1 expression. J Exp Med (1990) 2.28
The relationship between specific tissue lesions and pain severity in persons with knee osteoarthritis. Osteoarthritis Cartilage (2006) 2.27
Mechanism of Nef-induced CD4 endocytosis: Nef connects CD4 with the mu chain of adaptor complexes. EMBO J (1998) 2.25
Sst2, a negative regulator of pheromone signaling in the yeast Saccharomyces cerevisiae: expression, localization, and genetic interaction and physical association with Gpa1 (the G-protein alpha subunit). Mol Cell Biol (1996) 2.20
Retrograde transport of Golgi-localized proteins to the ER. J Cell Biol (1998) 2.08
Noninvasive ultrasound imaging of inflammation using microbubbles targeted to activated leukocytes. Circulation (2000) 2.07
The 18-month impact of an emergency room intervention for adolescent female suicide attempters. J Consult Clin Psychol (2000) 2.05
Cloning and characterization of murine p16INK4a and p15INK4b genes. Oncogene (1995) 2.05
The plasma membrane as a combat zone in the HIV battlefield. Genes Dev (2000) 2.02
Toward cataloguing all rice genes: large-scale sequencing of randomly chosen rice cDNAs from a callus cDNA library. Plant J (1994) 2.02
Evidence for a stable interaction of gp41 with Pr55(Gag) in immature human immunodeficiency virus type 1 particles. J Virol (2000) 2.00
Inhibition of G-protein signaling by dominant gain-of-function mutations in Sst2p, a pheromone desensitization factor in Saccharomyces cerevisiae. Mol Cell Biol (1995) 1.99
Substitutions in the protease (3Cpro) gene of poliovirus can suppress a mutation in the 5' noncoding region. J Virol (1990) 1.96
End-of-life decision making: when patients and surrogates disagree. J Clin Ethics (1999) 1.83
Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. Hum Gene Ther (2000) 1.81
Retrotransposon-related DNA sequences in the centromeres of grass chromosomes. Genetics (1998) 1.80
The HIV-1 Nef protein acts as a connector with sorting pathways in the Golgi and at the plasma membrane. Immunity (1997) 1.78
The downregulation of CD4 and MHC-I by primate lentiviruses: a paradigm for the modulation of cell surface receptors. Immunol Rev (1999) 1.77
Blocked early-stage latency in the peripheral blood cells of certain individuals infected with human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1992) 1.76
Efficient replication of human immunodeficiency virus type 1 requires a threshold level of Rev: potential implications for latency. J Virol (1992) 1.74
Characterization of human immunodeficiency virus type 1 Vif particle incorporation. J Virol (1996) 1.69
Human immunodeficiency virus type 1 particles pseudotyped with envelope proteins that fuse at low pH no longer require Nef for optimal infectivity. J Virol (2001) 1.65
Arthritis prevalence and activity limitations in older adults. Arthritis Rheum (2001) 1.65
High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors. Blood (2000) 1.63
Genomic instability in induced stem cells. Cell Death Differ (2011) 1.63
The type I serine/threonine kinase receptor ActRIA (ALK2) is required for gastrulation of the mouse embryo. Development (1999) 1.59
On the convergent evolution of animal toxins. Conservation of a diad of functional residues in potassium channel-blocking toxins with unrelated structures. J Biol Chem (1997) 1.57
Regulation of catalase-peroxidase (KatG) expression, isoniazid sensitivity and virulence by furA of Mycobacterium tuberculosis. Mol Microbiol (2001) 1.56
Mutational analysis of HIV-1 Nef: identification of two mutants that are temperature-sensitive for CD4 downregulation. Virology (1996) 1.56
High-yield expression and functional analysis of Escherichia coli glycerol-3-phosphate transporter. Biochemistry (2001) 1.56
Vascular smooth muscle cell phenotypic modulation in culture is associated with reorganisation of contractile and cytoskeletal proteins. Cell Motil Cytoskeleton (2001) 1.55
Mycobacterial FurA is a negative regulator of catalase-peroxidase gene katG. Mol Microbiol (2001) 1.53
The Nef protein of human immunodeficiency virus type 1 enhances serine phosphorylation of the viral matrix. J Virol (1997) 1.52
Reversible inhibition of Hsp70 chaperone function by Scythe and Reaper. EMBO J (2001) 1.50
p300 and ATF-2 are components of the DRF complex, which regulates retinoic acid- and E1A-mediated transcription of the c-jun gene in F9 cells. Genes Dev (1998) 1.50
Reversible immortalization of human primary cells by lentivector-mediated transfer of specific genes. Mol Ther (2000) 1.48
BAG-1, a negative regulator of Hsp70 chaperone activity, uncouples nucleotide hydrolysis from substrate release. EMBO J (1998) 1.48
Nef enhances human immunodeficiency virus type 1 infectivity resulting from intervirion fusion: evidence supporting a role for Nef at the virion envelope. J Virol (2001) 1.45
The role of the vagal pathway and gastric dopamine in the gastroparesis of rats after a 6-hydroxydopamine microinjection in the substantia nigra. Acta Physiol (Oxf) (2014) 1.44
Purification, cloning and sequence analysis of RsrI DNA methyltransferase: lack of homology between two enzymes, RsrI and EcoRI, that methylate the same nucleotide in identical recognition sequences. Nucleic Acids Res (1989) 1.43
Noninvasive imaging of inflammation by ultrasound detection of phagocytosed microbubbles. Circulation (2000) 1.43
The cellular inhibitor of the PKR protein kinase, P58(IPK), is an influenza virus-activated co-chaperone that modulates heat shock protein 70 activity. J Biol Chem (1999) 1.43
A stable system for the high-titer production of multiply attenuated lentiviral vectors. Mol Ther (2000) 1.43
Cloning and functional characterization of the human sodium-dependent vitamin C transporters hSVCT1 and hSVCT2. FEBS Lett (1999) 1.42
Bag1 functions in vivo as a negative regulator of Hsp70 chaperone activity. Mol Cell Biol (2000) 1.41
Pseudomonas aeruginosa possesses homologues of mammalian phenylalanine hydroxylase and 4 alpha-carbinolamine dehydratase/DCoH as part of a three-component gene cluster. Proc Natl Acad Sci U S A (1994) 1.40
Lentivirus vector gene expression during ES cell-derived hematopoietic development in vitro. J Virol (2000) 1.38
Nef-mediated clathrin-coated pit formation. J Cell Biol (1997) 1.38
Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels. Int J Tuberc Lung Dis (2007) 1.37
A massive, cooling-flow-induced starburst in the core of a luminous cluster of galaxies. Nature (2012) 1.36
Oxidative stress response and characterization of the oxyR-ahpC and furA-katG loci in Mycobacterium marinum. J Bacteriol (1998) 1.36
Lifetime and novel psychiatric disorders after pediatric traumatic brain injury. J Am Acad Child Adolesc Psychiatry (2001) 1.36
Intracellular water-specific MR of microbead-adherent cells: the HeLa cell intracellular water exchange lifetime. NMR Biomed (2008) 1.35
The blocks to human immunodeficiency virus type 1 Tat and Rev functions in mouse cell lines are independent. J Virol (1993) 1.34
The Nef protein of primate lentiviruses. Rev Med Virol (1999) 1.34
Validity and sensitivity to change of the extended Glasgow Outcome Scale in mild to moderate traumatic brain injury. J Neurotrauma (2001) 1.32
The proteolytic cleavage of human immunodeficiency virus type 1 Nef does not correlate with its ability to stimulate virion infectivity. J Virol (1998) 1.32
Silencing of oxidative stress response in Mycobacterium tuberculosis: expression patterns of ahpC in virulent and avirulent strains and effect of ahpC inactivation. Infect Immun (2001) 1.29
The efficacy of anal fistula plug in fistula-in-ano: a systematic review. Colorectal Dis (2010) 1.28
Overexpression of Na+/Ca2+ exchanger alters contractility and SR Ca2+ content in adult rat myocytes. Am J Physiol Heart Circ Physiol (2001) 1.24
HIV-1 latency due to the site of proviral integration. Virology (1993) 1.23
Prevalence of the metabolic syndrome among South Korean adults: the Ansan study. Diabet Med (2004) 1.22
Molecular cloning and functional expression of a brain-specific somatostatin receptor. Proc Natl Acad Sci U S A (1992) 1.19
Neutral glycolipids of migrating and nonmigrating rabbit corneal epithelium in organ and cell culture. Invest Ophthalmol Vis Sci (1990) 1.19